 - Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the American College of Cardiologys 70th Annual Scientific Session - MONTREAL and Charlotte, N.C., May 17, 2021 PRNewswire -- Milestone Pharmaceuticals Inc. Nasdaq: MIST, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of data related to key secondary endpoints from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Companys novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia PSVT. 